Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.
BioRestorative Therapies develops regenerative medicine products using cell and tissue protocols, primarily involving adult stem cells. News about BRTX centers on BRTX-100, its autologous hypoxic-cultured mesenchymal stem cell therapy for chronic lumbar disc disease, including clinical trial updates, safety and efficacy data presentations, and regulatory interactions tied to the program.
The company also reports developments involving its ThermoStem metabolic program and its commercial BioCosmeceutical platform. Recurring updates include scientific conference presentations, collaborations supporting BioCosmeceutical commercialization, capital actions, shareholder communications, and business updates related to development spending and platform expansion.
BioRestorative Therapies, Inc. (BRTX) announced its participation in the Roth 35th Annual Conference from March 12-14, 2023, at The Ritz Carlton, Laguna Niguel in Dana Point, California. CEO Lance Alstodt will be available for one-on-one meetings and provide updates on the company's pipeline, including the ongoing Phase 2 clinical trial for BRTX-100, targeting chronic lumbar disc disease. BioRestorative focuses on cell-based therapies, emphasizing its lead product for disc disorders and a metabolic program aimed at obesity. More information about the conference can be found on their official website.
BioRestorative Therapies (BRTX) announced a notice of allowance for a patent on its ThermoStem® program, which targets obesity and metabolic disorders, including type 2 diabetes. Issued on February 24, 2023, this marks the third patent in the ThermoStem family. The new patent covers implantable three-dimensional scaffolds and brown adipocytes derived from human stem cells. CEO Lance Alstodt stated this advancement strengthens the company's technology and opens doors for collaborations. BioRestorative also develops a disc/spine therapy using autologous stem cells.
BioRestorative Therapies (BRTX) announced a significant milestone with the European Patent Office issuing a notice of allowance for a patent related to its ThermoStem® program on February 6, 2023. This patent, which covers implantable three-dimensional scaffolds derived from human brown adipose stem cells, aims to treat obesity and metabolic disorders like type 2 diabetes. The technology combines scaffolds for cell delivery with brown adipose-derived stem cells, potentially benefiting multi-billion dollar markets.
CEO Lance Alstodt emphasized the importance of this patent in enhancing development capabilities in Europe, furthering their commitment to addressing metabolic disorders.
BioRestorative Therapies (BRTX) has received a Phase I SBIR grant from the NIH to advance its ThermoStem program aimed at treating Polycystic Ovary Syndrome (PCOS). This grant supports a partnership with Dr. Sheng Wu from Temple University, focusing on developing therapeutic brown adipocyte transplantation for PCOS patients, a condition affecting 6-18% of reproductive-age women. PCOS carries high annual healthcare costs of $4.36 billion in the US, highlighting the need for effective treatments.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) announced an exclusive licensing agreement with Regenexx, LLC for technology addressing chronic lumbar disc disease. This intellectual property will enhance BRTX's lead program, BRTX-100, currently in Phase 2 trials across about 15 sites in the U.S. The CEO, Lance Alstodt, emphasized the importance of this milestone for creating non-invasive treatments aimed at the $40 billion spent annually on surgical procedures. The technology utilizes hypoxia to improve cell-based therapies' efficacy and safety.
MELVILLE, N.Y., Nov. 29, 2022 - BioRestorative Therapies, Inc. (BRTX) announces CEO Lance Alstodt's participation in the RHK Capital Disruptive Growth Conference in New York City on December 5-6, 2022. This event will gather executives from 30 disruptive companies and institutional investors, market analysts, and financial advisors. BioRestorative focuses on therapeutic products utilizing adult stem cells for treating spinal and metabolic disorders, featured in their core programs brtxDISC™ and ThermoStem®.
BioRestorative Therapies, Inc. (Nasdaq: BRTX) has announced its participation in the RHK Capital Disruptive Growth Conference scheduled for December 5-6, 2022, in New York City. Lance Alstodt, the company's President and CEO, will engage in one-on-one meetings to discuss the latest updates on the company's expanded pipeline and ongoing Phase 2 clinical trial targeting chronic lumbar disc disease. The trial utilizes the BRTX-100 cell therapy, which aims to provide non-surgical treatment for painful lumbosacral disc disorders.
BioRestorative Therapies (NASDAQ: BRTX) announced an upcoming interview with CEO Lance Alstodt on Famela and Friends Talk Radio, focusing on the company's clinical development pipeline. BioRestorative is currently conducting a Phase 2 trial for its lead therapy candidate, BRTX-100, aimed at treating chronic lumbar disc disease. The trial involves up to 99 patients across 15 U.S. centers, assessing safety and efficacy. The company also highlighted its Metabolic Program utilizing stem cells from brown adipose tissue.
BioRestorative Therapies (NASDAQ: BRTX) announced CEO Lance Alstodt will present at the Dawson James Securities 7th Annual Small Cap Growth Conference on October 12, 2022, in Jupiter, Florida. The presentation will cover the company's Phase 2 clinical trial using BRTX-100, aimed at treating chronic lumbar disc disease. This double-blind trial will involve up to 99 patients at 15 sites in the U.S., comparing the investigational drug to a control group.
For live webcasts and details, visit BioRestorative's website.
BioRestorative Therapies (NASDAQ: BRTX) announced that CEO Lance Alstodt will speak at the Roth Inaugural Healthcare Opportunities Conference on October 6, 2022, in New York City. He will provide updates on the Phase 2 clinical trial of BRTX-100, a stem cell therapy aimed at treating chronic lumbar disc disease. The trial involves up to 99 patients across 15 sites, comparing the investigational treatment against a control.
Meetings with management can be arranged through Roth representatives.